ChiCTR2400088269: A real-world study evaluating the safety and efficacy of Mirvetuximab Soravtansine (MIRV) in platinum-resistant ovarian, primary peritoneal, or fallopian tube cancer with high folate receptor alpha expression |
|
|
| Recruiting | N/A | 50 | | None | Shanghai Jiao Tong University School of Medicine Affiliated Ruijin Hospital Hainan Hospital; Hangzhou ZhongMei Huadong Pharmaceutical Co., Ltd., Hangzhou ZhongMei Huadong Pharmaceutical Co., Ltd. | High expression of folate receptor alpha in platinum-resistant advanced high-grade ovarian, primary peritoneal, or fallopian tube cancer | | | | |
